Trial Profile
A Study Assessing The Effects Of Fingolimod On Cardiovascular Autonomic Modulation (CAM) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) After Two Years Of Continuous Daily Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 05 May 2017 New trial record
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.